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Curcumin is a natural compound derived from the spice, turmeric, that has been extensively 
reported for its efficacy in controlling or treatment of several inflammatory diseases. There is a 
growing body of literature that recognizes the anti-inflammatory effects of curcumin in the 
immune system. On the other hand, the role of inflammatory signaling pathways has been 
highlighted in the pathogenesis of several inflammatory diseases and signaling molecules 
involved in these pathways are considered as valuable targets for new treatment approaches. 
We aimed to provide a comprehensive overview of the modulatory effects of curcumin on 
inflammatory signaling pathways which leads to inhibition of inflammation in different types of 
immune cells and animal models. In this comprehensive review, we elaborate on how curcumin 
can effectively inhibit multiple signaling molecules involved in inflammation including NF-κB, 
JAKs/STATs, MAPKs, β-catenin, and Notch-1.  












HSPs              Heat shock proteins 
LPS                Lipopolysaccharide 
DCs                Dendritic cells 
TNF-α            Tumor necrosis factor-α 
IL                   Interleukin           
IFN                Interferon 
NF-κB            Nuclear factor-κB 
JAK/STAT     Janus kinase/Signal transducer and activator of transcription 
MAPK           Mitogen-activated protein kinase 
IBD               Inflammatory bowel disease 
RA                  Rheumatoid arthritis 
SLE                Systemic Lupus Erythematosus 
MS                 Multiple sclerosis 
T1DM            Type 1 diabetes mellitus 
IκB                 Inhibitors of NF-κB 
IKK                IκB kinase 
BMECs         Brain microvascular endothelial cells 
HUVECs      Human umbilical vein endothelial cells 
ICAM-1       Intercellular adhesion molecule 1 
VCAM-1      Vascular cell adhesion molecule 1 
MCP-1         Monocyte chemoattractant protein-1 
PPARγ         Peroxisome proliferator-activated receptor-gamma 
iNOS          Inducible nitric oxide synthase 
COX-2       Cyclooxygenase-2 
SHP2         Src homology 2 domain-containing protein tyrosine phosphatase 
OSM         Oncostatin M 
MMP         Matrix metalloproteinase 
EAE          Experimental allergic encephalomyelitis 
RORγt       RAR-related orphan receptor gamma 
TGF-β       Transforming growth factor β 
SOCS        Suppressor of cytokine signaling 
PIAS         Protein inhibitor of activated STAT 
ERK Extracellular receptor-activated kinase 
JNK C-Jun N-terminal kinase 
PGE2        Prostaglandin E2 
MPO        Myeloperoxidase 
CMF        Colonic myofibroblasts 
ROS         Reactive oxygen species 
BBB         Blood-brain barrier 
FLS Fibroblast-like synoviocyte 
LDH         Lactate dehydrogenase 
OGD        Oxygen-glucose deprivation 
GSK3       Glycogen synthase kinase 3    
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GATA3    Transcription factor GATA binding protein 3 
TAK1       Transforming growth factor (TGF)-activated kinase 1 
PMA        Phorbol 12-myristate 13-acetate 
DLN         Draining lymph node 
CRP C-reactive protein 























Inflammation and inflammatory signaling pathways 
Inflammation is one of the major types of immune responses. It has an important role in both 
innate and adaptive immunity and has a crucial role in the defense against many harmful stimuli, 
of both endogenous and exogenous origin [1,2]. During the inflammatory process, several 
immune cells (such as leucocytes) and plasma proteins (such as cytokines, complement proteins) 
are brought into the site of infection or damage in tissues and subsequently activated [3]. These 
blood-derived components of the immune system mediate inflammation to eliminate invading 
pathogens (such as bacteria, viruses, and fungi) and also promote tissue repair [4,5]. The immune 
system has evolved to recognize the molecular structures of both foreign and endogenous 
molecules [such as lipopolysaccharide (LPS), heat shock proteins (HSPs)] by receptors expressed 
by cells of the immune system such as macrophages, dendritic cells (DCs), endothelial cells, B 
cells, and T cells [1,6,7]. As a consequence of binding of these receptors to their ligands, 
intracellular signal transduction pathways are activated to initiate and promote inflammatory 
responses in immune cells against the above-mentioned agents [8,9,7]. During the inflammatory 
response, several inflammatory mediators such as pro-inflammatory cytokines and chemokines 
are produced by immune cells [3,10,7].  The most important pro-inflammatory cytokines in the 
immune responses are tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), IL-6, IL-12, 
interferon-γ (IFN-γ) and IL-8 [3,7]. In addition, the interaction of the aforementioned cytokines 
with their receptors on the surface of immune cells also activates inflammatory signaling 
cascades in a positive feedback loop. The three main signaling pathways that mediate the 
inflammatory response in immune cells include nuclear factor-κB (NF-κB) signaling pathway, 
Janus kinase/Signal transducer and activator of transcription (JAK/STAT) signaling pathway, and 
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mitogen-activated protein kinase (MAPK) signaling pathway [11-13]. Inflammation is a protective 
biological response of the host immune system and is carefully controlled by several mechanisms 
[4,14,15]. However, failure in these mechanisms which tightly regulate inflammatory signaling 
pathways leads to unabated inflammation and generation of immune-mediated inflammatory 
diseases such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA), systemic lupus 
erythematosus (SLE), atherosclerosis and multiple sclerosis (MS)][16-19]. Therefore, modulation 
of these signaling molecules in the inflammatory signaling pathways can effectively induce anti-
inflammatory effects and could potentially be a valuable approach for the management of 
inflammatory diseases.  
One of the natural compounds that have shown potential anti-inflammatory properties and 
promise in the management or control of several inflammatory diseases is curcumin. Herein, 
provide a comprehensive overview of the modulatory effects of curcumin on the inflammatory 
signaling pathways which leads to inhibition of inflammation in different types of immune cells 
and animal models. 
Curcumin and its immunomodulatory effects 
Curcumin is a natural compound derived from Curcuma longa L. (also called turmeric, a member 
of Zingiberacea family) that is being used extensively for the management of several diseases. 
Research supports the critical roles played by curcumin and its analogs such as antibacterial, 
antiviral, antifungal, antioxidant, anti-inflammatory, hepatoprotective and anti-tumor activities 
[20-30]. In addition, it is well established that curcumin is considered to be a safe natural 
compound [31,20]. In recent years, there has been an increasing interest in using curcumin as an 
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immunomodulatory agent in the immune system. The immunomodulatory effect of curcumin 
arises from its interaction with a wide range of immune cells such as macrophages, DCs, B and T 
cells [32,33]. The anti-inflammatory properties of curcumin have been demonstrated in the 
human and animal models of several inflammatory disorders such as RA, SLE, MS, type 1 diabetes 
mellitus (T1DM), atherosclerosis, metabolic syndrome, periodontal disease, colitis, and 
Alzheimer’s disease [34,33,35,36]. Interestingly, recent evidence suggests that curcumin can 
reduce the pro-inflammatory cytokines such as IFN-γ, TNF-α, IL-1 and IL-8 via interaction with 
several signaling and transcription molecules such as NF-κB, JAKs/STASs, MAPKs and β-catenin 
[34,37-41]. In this narrative review, we demonstrate that curcumin interacts with various 
signaling molecules in the inflammatory signaling pathways, thereby acting as an anti-
inflammatory agent. 
Effect of Curcumin on the NF-κB signaling pathway 
NF-κB was first identified in the B cells as a nuclear protein that binds specifically to kappa 
enhancer motif sequences in the NF-kB target genes [42]. This master transcription factor plays 
an essential role in the inducible expression of many genes associated with the inflammatory 
responses in the immune system including antimicrobial peptides, chemokines and cytokines 
[43,44]. NF-κB proteins are located in the cytoplasm of the cells and repressed by their inhibitory 
proteins that are known as the inhibitors of NF-κB (IκBs) [42]. In response to various stimuli, the 
IκB becomes phosphorylated by an active IκB kinase (IKK), which results in the dissociation of IκB 
from NF-κB [44]. Subsequently, NF-κB is released, translocated to the nucleus and bind their DNA 
binding sites to regulate the transcription of a large number of genes [43,44].  
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There is increasing evidence that the mode of action of curcumin involves modulating the NF-κB 
pathway, which may be considered as one of the key targets of curcumin (Figure 1) [45-50]. The 
NF-κB network could be modulated at two stages: the inhibition of the NF-κB activation process, 
and by direct inhibition of NF-κB.  In this regard, Brennan et al. reported that curcumin could 
inhibit NF-κB activation by inhibiting the degradation of IκB-α and reacting with the NF-kB itself 
in TNF-activated Jurkat T lymphoma cells [51]. Curcumin may also interfere with the binding 
activity of NF-κB to the κB site in the IL-12p40 promoter, which significantly inhibits IL-12 
production in LPS-activated macrophages [52,53]. In addition, curcumin treatment inhibited the 
NF-kB activation induced by oxygen-glucose deprivation in injured brain microvascular 
endothelial cells (BMECs) [54]. Kim et al. reported that curcumin negatively regulates the 
production of pro-inflammatory cytokines (IL-1, IL-6, and TNF-α) from maturing DCs [55]. In 
addition, the curcumin-treated DCs manifested an impaired induction of TH1 responses and a 
normal cell-mediated immune response [55]. This indicates that the inhibitory effect of curcumin 
on DCs maturation, at least in part, could be derived from its actions on the NF-κB activation as 
a potential target [55].  
Further studies suggest that curcumin inhibits NF-κB signaling pathway by promoting the 
expression of IκB-α in activated human macrophages by influenza virus infection [56]. In addition, 
curcumin derivative BDMC33-treated macrophages showed an interrupted degradation of IκB, 
resulting in attenuation of NF-κB nuclear translocation [57]. As a consequence of this event, the 
production of several pro-inflammatory mediators including NO, TNF-α, and IL-1β was 
suppressed by curcumin [57]. Kumar and colleagues studied the effects of curcumin on the 
adhesion of monocytes to human umbilical vein endothelial cells (HUVECs) [58]. They 
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demonstrated that the anti-inflammatory activity of curcumin may be due, in part, to the 
inhibition of leukocyte recruitment [58]. Curcumin blocked the TNF-induced adhesion of 
monocytes to HUVECs by inhibiting the expression of adhesion molecules and TNF-mediated 
activation of NF-κB [58]. Cho et al. reported that curcumin has an inhibitory effect on the 
expression of IL-1β and IL-6 expression induced in TNF-α-treated HaCaT cells [59]. They suggested 
that curcumin exerts it’s anti-inflammatory and growth inhibitory effects by negative regulation 
of the NF-κB pathway [59]. Bisdemethoxycurcumin, the active component of turmeric, 
suppresses the production of inflammatory cytokines including TNF-α, IL-8, and IL-6 by inhibiting 
the NF-κB activation and IκB degradation in pharmacologically‑induced inflammation in the 
human mast cells [60].  
Pan et al. reported that a new synthetic curcumin analog (C66) decreased high glucose-induced 
over-expressions of intercellular adhesion molecule 1 (ICAM-1) or CD54 (an important ligand for 
β2 integrins), vascular cell adhesion molecule 1 (VCAM-1) and monocyte chemoattractant 
protein-1 (MCP-1). It also reduced renal macrophage infiltration and injury by suppressing NF-κB 
activation in diabetic mice [61]. 
Curcumin decreases the NF-κB activation in TCR-stimulated non-obese diabetic lymphocytes 
[62]. Moreover, Soetikno et al. observed that the administration of curcumin protects against the 
development of diabetic nephropathy [37]. Diabetic nephropathy is a major complication of 
diabetes and can be considered as an inflammatory disease [63]. Monocytes/macrophages as the 
main source of pro-inflammatory mediators including TNF-α, IL-1β, MCP-1 and are the key 
inflammatory cells involved in the pathogenesis of the diabetic nephropathy [64,65]. 
Macrophages infiltrating into the glomerulus are implicated in the development of glomerular 
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injury [64]. It has been indicated that curcumin could reduce macrophage infiltration by 
suppressing the activation of the NF-κB pathway in diabetic rat models [37]. In accord with this 
finding, Ghosh et al. demonstrated that curcumin treatment improves renal function in the 
animal models with chronic renal failure by antagonizing the effect of TNF-α in peroxisome 
proliferator-activated receptor-gamma (PPARγ) [66]. It also blocked transactivation of NF-κB [66].  
Effect of Curcumin on JAK/STAT signaling pathway 
The JAK/STAT signaling pathway is one of the most important pathways that regulate 
inflammation in immune cells by transducing the signal of types 1 and 2 cytokines receptors in 
response to various pro-inflammatory cytokines [67,13]. This pathway includes the four known 
Janus kinases (JAK1-3 and TYK2), which are associated with the aforementioned receptors, and 
seven STATs (STAT1-4, 5a, 5b, and 6) [67,13]. 
In innate immunity, these intracellular molecules mediate signaling cascades induced by type I 
and type II interferon (i.e., IFN-α/β and IFN-γ).  They can effectively induce the activation, 
maturation, and function of DCs and macrophages [68].  In acquired immunity, JAK/STAT 
signaling regulates the activation and differentiation of different subtype of T cells including TH1 
(JAK2, TYK2, STAT1, and STAT4), TH2 (JAK1, JAK3, and STAT6), and TH17 (STAT3) from naïve CD4+ 
T cells [13,67,69]. Despite the physiologic roles played by JAK/STAT signaling, this pathway is also 
involved in the pathogenesis of several inflammatory diseases such as RA, IBD, MS, T1DM, SLE, 




The inhibitory action of curcumin on JAK/STAT signaling pathway has been confirmed in a study 
conducted by Kim et al., where it was shown that curcumin suppresses phosphorylation of JAK1, 
JAK2 and their downstream molecules such as STAT1 and STAT3 in IFN-γ, gangliosides or LPS–
activated microglial cells. As a result, the expression of several pro-inflammatory mediators 
including inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), MCP-1 and ICAM-
1 were impaired in activated microglial cells [75]. In this regard, the activation of Src homology 2 
domain-containing protein tyrosine phosphatases (SHP)-2, a key negative regulator of JAK 
activity, is one of the several molecular mechanisms by which curcumin mediates suppression of 
JAK activation [75]. Oncostatin M (OSM) is an important member of IL-6 cytokine superfamily 
that is involved in the pathogenesis of several inflammatory diseases, such as RA, by inducing 
several matrix metalloproteinases (MMPs). In line with previous findings, it has been reported 
that curcumin treatment suppressed the OSM-induced phosphorylation and DNA binding activity 
of STAT1 (but not JAK1, JAK2, and JAK3) in bovine and human primary articular chondrocyte [76]. 
By its inhibitory action on STAT1, curcumin suppresses the OSM-induced production of MMP1, 
MMP3, and MMP13 in chondrocytes [76]. Another in vitro study assessing the mechanisms 
underlying curcumin-regulated JAK/STAT signaling  showed that curcumin potently inhibits the 
expression of LPS-induced IL-6, TNF-α, and COX-2 in macrophage cell line RAW264.7 via its 
modulatory effect on suppressor of cytokine signaling (SOCS)1 and SOCS3 [77]. SOCS proteins 
negatively regulate the overactivation of the JAK/STAT signaling in responses to inflammatory 
cytokines through interaction with both JAKs and STATs [78,79]. This evidence provides a novel 
molecular mechanism by which curcumin regulates the JAK-STAT-mediated inflammatory 
responses in macrophages. Another in vitro study suggested that curcumin reduced the 
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expression of several inflammatory mediators including ICAM-1, MCP-1, and IL-8 at both mRNA 
and protein levels by suppressing the STAT3-phosphorylation in TNF-α-stimulated HUVECs [80]. 
 
In experimental allergic encephalomyelitis (EAE), characterized by the predominance of auto-
reactive TH1 and TH17 cells responses, curcumin blocks the IL-12-induced phosphorylation of 
JAK2, TYK2 and their downstream molecules, i.e. STAT3 and SATA4 in T cells [81]. Curcumin also 
inhibits the production of IL-12 by macrophages and DCs [81-83]. With regard to the essential 
role of IL-12 in the differentiation of TH1 cells [84], curcumin can strongly suppress the 
proliferation and differentiation of auto-reactive TH1 cells in several autoimmune diseases such 
as MS via inhibition of IL-12 production and its signaling cascade. Similar to effects on TH1 cells, 
curcumin also effectively suppresses proliferation and differentiation of auto-reactive TH17 cells, 
another important subtype of T CD4+ cells involved in the pathogenesis of EAE [85]. This is 
mediated by both suppressing IL-6, IL-21, and IL-17 production, and by inhibiting STAT3-
phosphorylation and RAR-related orphan receptor gamma (RORγt) activation in response to the 
aforementioned cytokines [85]. It is interesting to note that IL-6 and IL-21 are required for the 
differentiation of TH17 cells from naïve CD4+ T cells by activating STAT3 signaling and its 
downstream transcription factor of RORγt [86,87]. Curcumin treatment attenuated CNS 
inflammation, demyelination and severity of clinical paralysis in animal models of EAE owing to 
its modulatory effects on JAK/STAT signaling [81,85]. This evidence is further supported by other 
studies which showed curcumin could exert its beneficial anti-inflammatory effects in an animal 
model of colitis and intestinal inflammation by inhibiting the phosphorylation of JAK2, STAT3 and 
STAT6 [88,40,89]. This is followed by downregulated protein expression of TNF-α, IL-1β, IFN-γ, IL-
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23, IL-12p70 and up-regulated expression of anti-inflammatory cytokines including IL-4, IL-10, IL-
13 and transforming growth factor β (TGF-β) [88,40,89]. In addition, curcumin also inhibits the 
activation of CD4+CD7- T cells by downregulation of the STAT-3 signaling pathway [90,91]. 
CD4+CD7- T cells are a distinct subset of CD4+ T cells which produce TH2-like cytokine profiles 
including IL-4 and IL-10. They are involved in the pathogenesis of several inflammatory skin 
diseases [92]. 
 DCs are key cells crucial for the initiation of pro-inflammatory responses in autoimmune and 
inflammatory diseases such as colitis and are one of the main targets of curcumin [93,94]. It has 
been documented that curcumin suppress activation and maturation of DCs in colitis mice by 
targeting JAK/STAT signaling and also by up-regulation of three important negative regulators of 
this pathway including SOCS 1 and 3 and protein inhibitor of activated STAT3 (PIAS3) [40,89].   
Taken together, this growing evidence provides a better understanding of the mechanism of anti-
inflammatory action for curcumin via modulating of JAK/STAT inflammatory signaling. 
Effect of Curcumin on MAPKs signaling pathway 
MAPKs are a group of serine-threonine protein kinases that contribute to gene induction, 
proliferation, cellular differentiation, and inflammatory responses [95]. There are three main 
groups of MAPKs which include extracellular receptor-activated kinase (ERK), P38 and C-Jun N-
terminal kinase (JNK) [96]. MAPKs play major roles in the production of pro-inflammatory 




In order to study the effect of curcumin on inflammation related to MAPKs signaling pathway, 
Morgana et al. investigated its effects on LPS-stimulated raw 264.7 murine macrophages and 
found that curcumin remarkably reduced prostaglandin E2 (PGE2) level and the expression of 
TNF-α and IL-6 by inhibiting phosphorylation and activation of p38 MAPK [77]. In addition, 
another in vitro study indicated that pretreatment of murine microglia cell line N9 with curcumin 
and demethoxycurcumin (DMC) could reduce LPS-induced phosphorylation of p38, JNK and 
ERK1/2 MAPKs pathways, resulting in inhibition of the production of ROS by microglial cells [98]. 
Consistent with previous studies, Kim et al., demonstrated that pretreatment of immature DCs 
cells with curcumin suppressed the LPS-induced maturation function of DCs by inhibiting 
phosphorylation of all three main MAPKs (JNK, p38, and ERK)[55]. Moreover, curcumin effectively 
inhibited COX-2 expressions (both in mRNA and protein levels) in UVB-irradiated HaCaT cells by 
an inhibitory action on activation of p38 MAPK and JNK [99]. 
RA is a chronic inflammatory disease characterized by the infiltration of several immune cells 
such as macrophage, DCs, T and B lymphocytes in the inflamed joints to produce pro-
inflammatory cytokines including IL-1β, IL-6, TNF-α, IFN-γ, IL-17, and IL-12 [100]. In response to 
these pro-inflammatory cytokines, resident synovial fibroblast cells also produce large amounts 
of IL-6, IL-8, COX-2, and MMPs which results in the progressive joint destruction, deformity, and 
disability [101,102]. Treatment of human synovial fibroblast cell line  MH7A and fibroblast-like 
synoviocytes (FLS) of RA patients with curcumin decreased PMA or IL-1β-induced 
phosphorylation of ERK1/2, but not p38, which led to reduced expression of IL-6 [103]. 
Dry eye disorder is a common inflammatory eye disease where hyperosmosis followed by the 
inflammation of the ocular surface is involved [104]. In addition, high expression of pro-
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inflammatory cytokines such as IL-1β and IL-6 has been observed in patients with dry eye disorder 
[105,106]. In a study by Min Chen et al., pretreatment of hyperosmotic-stimulated human 
corneal epithelial cells with curcumin prevented an increase in the IL-1β, IL-6 and TNF-α 
production. Interestingly, p38 inhibitor (SB 203580), but not JNK inhibitor (600125), has been  
able to completely inhibit the IL-1β production, suggesting that the potential anti-inflammatory 
effects of curcumin are mediated by its suppressive effect on p38 pathway. Importantly, p38 
inhibitor also reduced the activation of NF-κB, which proves that activation of the NF-κB occurs 
after the activation of p38 [107]. These findings provide evidence that curcumin is able to 
suppress NF-κB signaling cascade both through its direct interaction with NF-κB and by inhibition 
of its upstream activator (i.e. p38 MAPK).  
After brain ischemia, brain microvascular endothelial cells (BMECs), the principal cells in the 
blood-brain barrier (BBB), can cause inflammation by producing several inflammatory cytokines 
such as IL-1β [108]. Hence preventing inflammatory processes in BMECs can potentially reduce 
brain damage. In a study by Zhan et al., curcumin was able to significantly reduce the lactate 
dehydrogenase (LDH) release and IL-1β production in oxygen-glucose deprivation (OGD)-
stimulated BMECs via inhibition of p38 and JNK phosphorylation. In line with the Min Chen et al 
study, P38 inhibitor (SB203580) suppresses activation of NF-κB, suggesting that curcumin can 
potentially inhibit these two pathways simultaneously [54].  
In an animal model of colitis, curcumin treatment effectively reduced both myeloperoxidase 
(MPO) activity and production of TNF-α, COX-2 and iNOS by suppressing p38 phosphorylation. 
Moreover, the production of anti-inflammatory cytokine IL-10 was up-regulated [109]. These 
findings are in accord with a recent study suggesting that treatment of colonic mucosal biopsies 
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and colonic myofibroblasts (CMF) of IBD patients with curcumin resulted in reduced p38 
phosphorylation which was followed by a decrease in the IL-1β and MMP-3 production [110]. 
 
Asthma is a long-term chronic inflammatory disease characterized by the production of pro-
inflammatory cytokines such as TNF-α, and IL-1β in the airways [111,112]. MAPKs are one of the 
important factors in the production of these pro-inflammatory proteins, hence inhibiting this 
pathway can be a valuable treatment option for this disease [113]. In this regard, in a study by 
Singh et al., in an animal model of chronic asthma intranasal curcumin was able to inhibit all of 
the three main pathways of MAPKs (p38, JNK, and ERK) [114]. As a result, the levels of nitrite, 
COX-2 and reactive oxygen species (ROS) were significantly reduced [114]. 
Other Targets of Curcumin 
Curcumin has also shown immunomodulatory effects on different signaling molecules in the 
immune cells. Yang et al. demonstrated that treatment with curcumin down-regulated the 
expression of glycogen synthase kinase 3 (GSK-3), a negative regulator of Wnt/β-catenin signaling 
pathway and up-regulated the expression of β-catenin, a chief downstream transcription factor 
of the canonical Wnt signaling pathway, in LPS-stimulated BMDC [41]. As a result, Wnt/β-catenin 
signaling was activated in curcumin-treated BMDC that led to the inhibition of DCs activation and 
maturation [41]. In addition, in a mouse model of allergic asthma, administration of curcumin for 
9 days attenuated asthma symptoms and inflammatory responses in the airway by activating the 
Wnt/β-catenin signaling pathway, especially in DCs [41].  
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While investigating further molecular targets of curcumin and its anti-inflammatory effects, 
Cheong et al. found that treatment of mouse model of acute asthma with curcumin (200 mg/kg) 
decreased both mRNA and protein levels of Notch 1 receptor and it's downstream 
transcription factor GATA binding protein 3 (GATA3), a master regulator of TH2 cells 
differentiation, in lung tissues [115]. Notch 1-GATA3 signaling pathway plays a crucial role in the 
pathogenesis of allergic asthma by promoting the differentiation of TH2 cells [116-119]. 
Therefore, curcumin attenuated the allergic airway inflammation by inhibiting the Notch 1-
GATA3 signaling pathway and subsequent suppression of TH2 cells differentiation [115,120]. 
Recently, another in vivo study has shown that curcumin can also inhibit the phosphorylation of 
transforming growth factor (TGF)-activated kinase 1 (TAK1) in inflamed spinal cord cells which 
suppress production of pro-inflammatory cytokines,  including TNF-α, IL-1β, and IL-6 in a mouse 
model of acute spinal injury [121]. TAK1 is one of the MAPKKK family members and a major 
upstream modulator for the activation of NF-κB and P38 in microglial cells [122]. Therefore, 
curcumin can effectively suppress activation of these important pro-inflammatory transcription 
factors not only through direct interaction on NF-κB, P38 but also through their upstream 
molecules, especially TAK1,.  
Anti-inflammatory effects of curcumin in clinical trials 
Over the past decade, a large number of clinical studies has investigated the anti-inflammatory 
effects of curcumin in several diseases. In a randomized clinical trial conducted by Alizadeh et al., 
administration of 80 mg curcumin nanomicelle daily for 10 weeks significantly reduced plasma 
levels of inflammatory mediators including TNF-α and C-reactive protein (CRP) in infertile men 
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[123]. Another randomized clinical trial evaluating the anti-inflammatory effects of curcumin 
supplementation found that oral administration of 500 mg turmeric (containing 22.1 mg the 
active ingredient curcumin) for 2 months significantly reduced the serum levels of IL-8, but not 
TNF-α, in patients with type 2 diabetic nephropathy [124]. The anti-inflammatory effects of 
curcumin were further supported by a randomized clinical trial conducted by Panahi et al., which 
found that curcumin treatment (1 g/day) effectively reduced serum levels of TNF-α, IL-6, and 
MCP-1 in patients with metabolic syndrome [125]. In addition, a decrease in the plasma levels of 
IL-4 and IL-6 were observed after treatment of patients with knee osteoarthritis with pure 
curcuminoids (1500 mg/day) for 6 weeks [126]. Another clinical study found that oral 
administration of curcuminoids (comprising curcumin, demethoxycurcumin, and 
bisdemethoxycurcumin) at a daily dose of 1 g for 4 weeks significantly reduced serum 
concentration of IL-1β, IL-4 and vascular endothelial growth factor (VEGF), but not TNF-α, IL-6, 
IL-8, IFN-γ, and MCP-1 in obese individuals [127]. Moreover, by reducing TNF-α, IL-8, IL-6, MCP-
1, and hs-CRP, curcumin effectively mediated its anti-inflammatory effects in sulfur mustard-
intoxicated patients with chronic pulmonary or cutaneous complications. This disease is 
characterized by the overproduction of several pro-inflammatory cytokines [128,129]. In line 
with the findings of previous studies, anti-inflammatory effects of curcumin were also reported 
in a clinical study where it has been shown that administration of curcumin (180 mg/day) for 8 
weeks resulted in a reduction of serum levels of pro-inflammatory mediators including TNF-α, IL-
8, IL-6, MCP-1, and hs-CRP in patients with solid tumors. As a consequence, systemic 
inflammation in these patients was suppressed by curcumin supplementation [130]. All of the 
studies reviewed here have demonstrated the anti-inflammatory effects of curcumin in several 
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diseases by its modulatory effects on inflammatory signaling pathway as the main targets of 
curcumin. Table 2 summaries anti-inflammatory effects of curcumin in recently completed 
clinical trials. 
Concluding remarks 
There is growing evidence that curcumin through interaction with a diverse set of cellular and 
molecular targets, has an anti-inflammatory role and therefore can be considered as a valuable 
natural compound for managing various inflammatory diseases. Curcumin can inhibit the 
inflammatory process in different types of immune cells and animal models (Table 1, Figure 1). 
Curcumin has been found to suppress several inflammatory cascades in immune cells which 
result in 1) inhibition of activation, maturation and cytokines production of two important cells 
of innate immunity i.e. macrophages and DCs, and (2) inhibition of activation, proliferation, 
maturation and cytokines production of T cell subsets such as TH1, TH2 and TH17. Interestingly, 
curcumin as a pleiotropic molecule can simultaneously target multiple signaling molecules such 
as NF-κB, JAKs/STATs, MAPKs and Wnt/β catenin, suggesting its potential as a signaling molecule-
targeted therapeutic agent for inflammatory and immune-related diseases.   
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Table 1. A brief overview of molecular targets of curcumin and its anti-inflammatory effects; (-) and 





Biologic effects Targets  Ref. 





- Inhibit NF-κB activation by interfering with IκBα 
degradation 








- Inhibit  interleukin-12 production 
NF-κB (-) 
NF-κB binding 
to the κB site (-) 
[52] 
- In vitro 
OGD- treated 
BMECs 
- Reduce LDH release 
- Decrease IL-1β production 





- In vitro 
LPS-stimulated 
BMDCs 
- Inhibit expression of co-stimulatory molecules 
including CD80, CD86, and MHC class II 
- Induce the immature state of DCs with high endocytic 
capacity 
- Inhibit the capacity of DC to induce TH1 responses 
- Inhibit production of IL-12, IL-1β, IL-6, and TNF-α 














- In vitro 
TNF-α-stimulated 
HUVECs 
- Inhibit cell surface expression of ICAM-1, VCAM-1, 
and ELAM-1 
-Blocked their adhesion to monocytes 
NF-κB (-) [58] 
- In vitro 
TNF-α-treated 
HaCaT cells 






- In vitro 
PMA and calcium 
ionophore 
A23187-treated 
human mast cells 






- In vivo 
Renal epithelial 
NRK-52E cells 
- Inhibit high glucose-induced over-expressions of 
ICAM-1, VCAM-1, and MCP-1 











- In vitro 
 
 
Splenocytes in an 
animal model of  
diabetes 
- Inhibit pancreatic leucocyte infiltration 
- Impair proliferation and IFN-γ production 









- Inhibit expression of co-stimulatory molecules 
including CD80, CD86, CD40, and MHC class II 
- Reduce production of IL-12p70, IL-6, and TNF-α 




An animal model 
of  diabetes 
- Decrease TNF-α, IL-1β, ICAM-1, MCP-1 protein 
expression 


















DLN cells - Decrease proliferation 
- Reduce mRNA expression of IL-17, TGF-β, IL-6, IL-21, 
and RORγt 
STAT3 (-) [85] 
Jurkat T cells 
Spinal cord cells 
of an animal 
model of  EAE 





Spleen cells in 
animal model of  
EAE 
- Decrease proliferation and IL-12-induced responses 








of an animal 
model of  EAE 
- Decrease IL-12 production 
Mouse microglial 
cell line 





















































cells of an animal 
model of  colitis 
- Reduce expression of TNF-α and IL-1β 
- Inhibit activity of MPO 






cells of an animal 
model of  colitis 
- Inhibit activity of MPO 
- Reduce production of TNF-α, IFN-γ 
- Increase production of IL-10, IL-13, and TGF-β 








an animal model 
of  colitis 
- Decrease the total number of DCs 
- Reduce expression of co-stimulatory molecules on 












- Reduce mRNA expression of IL-6, TNF-α, and IL-1β 







cells of an animal 
model of colitis 
- Inhibit activity of MPO 
- Reduce production of TNF-α 
- Increase production of IL-10 
- Reduce expression of COX-2 and iNOS 







- Decrease IL-1β and MMP-3 production 
- Increase production of  IL-10 
p38 (-) [110] 
- In 
vivo 
Animal model of 
Chronic asthma 










cell line N9 







MH7A cells and 
RA-FLS 















- Inhibit maturation and function of BMDCs. 




Lung tissues of a 
mouse model of 
asthma 




Lung tissues of a 
mouse model of 
asthma 









Spinal cord cells 
of a mouse 
model of acute 
spinal cord injury 
- Inhibit production of pro-inflammatory cytokines, 
including TNF-α, IL-1β, IL-6, and NO 

















60 Infertility 80 mg/day 10 weeks 
Reduced 
plasma level of 
TNF-α and CRP 
[123] 
40 
Type 2 diabetic 
nephropathy 
66.3 mg/day 2 month 
Decreased 
plasma and 






1 g/day 8 weeks 
Reduced 
plasma level of 






1500 mg/day 6 weeks 
Reduced 
plasma level of 
IL-4 and IL-6 
[126] 
50 Osteoarthritis 200 mg/day 3 month 
Reduced 
plasma level of 
CRP 
[131] 
100 Osteoarthritis 200 mg/day 8 month 






30 Obesitiy 1 g/day 4 weeks 
Reduced 
plasma level of 






1.5 g/day 4 weeks 
Reduced 
plasma level of 









1 g/day 4 weeks 
Reduced 
plasma level of 
IL-8 and hs-CRP 
[129] 
80 Solid tumors 180 mg/day 8 weeks 
Reduced 
plasma level of 







1.648 g/day 8 weeks 
Reduced 








1.648 g/day 8 weeks 
Attenuated the 
increase in the 




Type 2 diabetes 
mellitus. 
1500 mg/day 8 weeks 
Reduced 
plasma level of 
TNF-α and IL-6 
[135] 
237 
Type 2 diabetes 
mellitus. 
1500 mg/day 9 month 
Increased 
plasma level of 
adiponectin 
[136] 
71 Hemodialysis 66.3 mg/day 12 weeks 
Reduced 
plasma level of 
TNF-α, IL-6, and 
hs-CRP 
[137] 
72 Migraine 80 mg/day 2 month 
Reduced 
plasma level of 
ICAM-1 
[138] 
80 Migraine 80 mg/day 2 month 
Reduced 
plasma level of 
IL-6, and hs-CRP 
[139] 
74 Migraine 80 mg/day 2 month 
Reduced 
plasma level of 
TNF-α 
[140] 
74 Migraine 80 mg/day 2 month 
Reduced 
plasma level of 
COX-2/iNOS 
[141] 






plasma level of 










plasma level of 





 5-50 µM 0.5-24 h 
Reduced 
plasma level of 
IL-1 and MMP-3 
Increased 














Figure 1. A schematic view of curcumin's modulatory effects on NF-κB, JAK/STAT, and MAPKs pathway. Curcumin 
suppresses activation and phosphorylation of JAKs and STATs proteins. Moreover, curcumin via both direct 
interactions with NF-κB and IκB suppresses activation of NF-κB. Finally, curcumin inhibits MAPK signaling pathway 
via its interaction with three main members of this pathway including JNK, p38, and ERK. As a result of curcumin's 
modulatory functions, the pro-inflammatory process including infiltration of leukocyte into the site of inflammation, 
activation, maturation and also the production of pro-inflammatory mediators by innate immune cells strongly was 
inhibited. On the other hand, curcumin suppresses acquired immune responses by its inhibitory effects on the 
activation, differentiation and cytokines production of T cells. 
